Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study.
K K Venkatesh, C W Chiang, W C Castillo...
https://pubmed.ncbi.nlm.nih.gov/34605130/Actively Recruiting
Led by Ohio State University · Updated on 2026-10-07
1572
Participants Needed
26
Research Sites
52 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of oral metformin compared to injectable insulin in treating gestational diabetes mellitus GDM in pregnant individuals. This phase 4, randomized controlled trial aims to determine whether metformin is not worse than insulin in reducing adverse pregnancy outcomes and to assess patient-reported experiences and long-term safety for both mothers and their children. The study involves 1,572 pregnant individuals with GDM requiring medication, recruited from 20 U.S. sites, with follow-up through delivery and up to two years postpartum. Participants are randomly assigned to one of two treatment groups the metformin group or the insulin group. Those in the metformin group will take oral metformin tablets, either immediate- or extended-release, up to a maximum daily dose of 2,500 mg, with insulin added if needed due to insufficient blood sugar control or intolerance. The insulin group will receive injectable insulin, which may include basal and prandial insulins, with dosing adjusted by trimester and weight, following clinical standards. Treatments reflect usual clinical practice, and the trial is open-label without masking. Throughout the study, participants and their children will be monitored with evaluations including pregnancy outcomes, neonatal health, and child growth up to two years of age. Assessments will include maternal health measures such as hypertensive disorders, weight gain, delivery method, and metabolic profiles, as well as child body mass index and other growth indicators. Patient-reported outcomes will be collected at six weeks and two years postpartum. Safety and treatment satisfaction will be tracked, with data collected during routine care and scheduled follow-up visits.
CONDITIONS
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
K
Kartik Venkatesh, MD, PhD
A
Anna Bartholomew, MPH, BS, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ohio State University
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Metformin | Insulin | Insulin (standard care) |
|---|---|---|---|
| What it is | Oral glucose‑lowering medication studied as the investigational option for GDM | Injectable insulin studied as the comparator arm in the trial | Insulin is the recommended first‑line pharmacologic treatment for GDM when lifestyle changes are insufficient |
| Role in the trial | Randomized investigational treatment arm | Randomized comparator treatment arm | Represents current usual care outside the trial |
| Primary use | Lower blood glucose in GDM via oral medication | Lower blood glucose in GDM via injectable therapy | Achieve glycemic targets when diet and lifestyle alone are not sufficient |
| How it is administered | Taken orally as metformin tablets | Administered by injection as insulin | Administered by injection in routine clinical practice |
| Current evidence | Evidence from previous trials (MiG trial) shows metformin alone or with supplemental insulin gives similar perinatal outcomes compared to insulin | Long‑standing use with established efficacy to maintain glucose control in GDM | Strong clinical guideline support as first‑line pharmacologic therapy when lifestyle measures fail |
| Important risks | Metformin crosses the placenta; long‑term effects on offspring metabolic outcomes remain under study | Injectable insulin may cause maternal hypoglycemia if dosing or monitoring is suboptimal | Hypoglycemia remains a clinical consideration when using insulin in routine care |
| Important limitations | May not be sufficient in individuals with high fasting glucose or pregestational diabetes—some may need supplemental insulin | Requires injections, frequent glucose monitoring, and may be more burdensome to manage | In routine practice insulin demand entails training and adherence support resources |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual)
Duration - From randomization at 20 to 33 weeks gestation until delivery
Participants receive either oral metformin or injectable insulin for gestational diabetes management, with doses adjusted as needed according to clinical standards.
Regular visits during pregnancy as per clinical practice
Duration - Up to 2 years postpartum
Participants and their children are monitored for health outcomes including maternal and child growth, metabolic status, and patient-reported experiences up to two years after delivery.
Scheduled follow-up visits at 6 weeks and throughout 2 years postpartum
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
K K Venkatesh, C W Chiang, W C Castillo...
https://pubmed.ncbi.nlm.nih.gov/34605130/Kartik K Venkatesh, Cora MacPherson, Rebecca G Clifton...
https://pubmed.ncbi.nlm.nih.gov/39317491/Kartik K Venkatesh, Courtney D Lynch, Camille E Powe...
https://pubmed.ncbi.nlm.nih.gov/35412565/Kartik K Venkatesh, Jiqiang Wu, Anne Trinh...
https://pubmed.ncbi.nlm.nih.gov/38049101/Ohio State University
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor